Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NPD-1902 is an oligonucleotide therapeutic under development by Nogra Pharma for the treatment of immune-inflammatory-mediated diseases, with a specific focus on Crohn's disease. Part of the company's proprietary oligonucleotide platform, NPD-1902 is designed to modulate disease-associated protein expression by down-regulating target proteins involved in inflammatory pathways. While the specific molecular target remains undisclosed, the candidate is currently in the formulation development stage of preclinical research, following the company's strategy of utilizing oligonucleotide-based modalities to address chronic inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NPD-1902.